acute_lymphoblastic_leukaemia_smear

Azacitidine and nivolumab combo proves successful in phase II trial

pharmafile | November 13, 2018 | News story | Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas 

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or refractory acute myeloid leukaemia (AML) in a phase II trial, led by Professor Naval Daver the University of Texas MD Anderson Cancer Center.

The phase II trial demonstrated that 22% of the 70 patients went into complete remission following the combination treatment. While participants had on average already undergone two prior treatments for relapsed AML, the response rate was 33% overall.

However around 11% of patients suffered from severe or potentially life threatening side effects, the majority of which were treated successfully. The average overall survival was just over 6 months. Due to the encouraging results, researchers have initiated a phase III trial.

Daverat commented: “We believe that implementation of clinical and immune biomarkers to select patients are likely to yield further improved outcomes with these types of therapies in AML.

Louis Goss

Related Content

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from …

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast …

Latest content